Eagle Pharmaceuticals Inc (EGRX.OQ)
EGRX.OQ on NASDAQ Stock Exchange Global Market
54.94USD
20 Apr 2018
54.94USD
20 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$54.94
$54.94
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
97,546
97,546
52-wk High
$97.14
$97.14
52-wk Low
$45.05
$45.05
Consensus Recommendations
Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
---|---|---|---|
Outperform | 1.00 | December | 24 Apr 2018 |
Analyst Recommendations and Revisions
1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
---|---|---|---|---|
(1) BUY | 1 | 1 | 1 | 1 |
(2) OUTPERFORM | 2 | 2 | 2 | 2 |
(3) HOLD | 0 | 0 | 0 | 0 |
(4) UNDERPERFORM | 1 | 1 | 1 | 1 |
(5) SELL | 0 | 0 | 0 | 0 |
No Opinion | 0 | 0 | 0 | 0 |
Mean Rating | 2.25 | 2.25 | 2.25 | 2.25 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
# of Estimates | Mean | High | Low | 1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 4 | 50.79 | 55.15 | 47.00 | 66.70 |
Quarter Ending Sep-18 | 4 | 50.05 | 51.20 | 47.39 | 86.00 |
Year Ending Dec-18 | 4 | 201.06 | 205.70 | 189.90 | 268.96 |
Year Ending Dec-19 | 4 | 220.98 | 235.80 | 210.30 | 343.83 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 4 | 1.00 | 1.08 | 0.92 | 1.19 |
Quarter Ending Sep-18 | 4 | 0.96 | 1.15 | 0.75 | 1.78 |
Year Ending Dec-18 | 4 | 3.70 | 4.06 | 3.27 | 4.30 |
Year Ending Dec-19 | 4 | 4.18 | 4.53 | 3.96 | 6.48 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
---|---|---|---|---|
SALES (in millions) | ||||
Quarter Ending Dec-17 | 52.91 | 46.78 | 6.12 | 11.58 |
Quarter Ending Sep-17 | 51.86 | 63.02 | 11.16 | 21.53 |
Quarter Ending Jun-17 | 52.52 | 50.11 | 2.41 | 4.59 |
Quarter Ending Mar-17 | 70.37 | 76.79 | 6.42 | 9.12 |
Quarter Ending Dec-16 | 85.95 | 81.14 | 4.81 | 5.60 |
Earnings (per share) | ||||
Quarter Ending Dec-17 | 1.00 | 1.00 | 0.00 | 0.50 |
Quarter Ending Sep-17 | 0.80 | 1.22 | 0.42 | 52.98 |
Quarter Ending Jun-17 | 0.51 | 0.28 | 0.23 | 45.10 |
Quarter Ending Mar-17 | 1.41 | 1.42 | 0.00 | 0.35 |
Quarter Ending Dec-16 | 2.82 | 3.52 | 0.70 | 24.93 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 50.79 | 51.02 | 51.43 | 57.15 | 66.70 |
Quarter Ending Sep-18 | 50.05 | 50.21 | 49.88 | 56.75 | 86.00 |
Year Ending Dec-18 | 201.06 | 203.07 | 204.25 | 211.40 | 268.96 |
Year Ending Dec-19 | 220.98 | 223.43 | 224.08 | 223.93 | 343.83 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 1.00 | 0.99 | 1.01 | 1.33 | 1.19 |
Quarter Ending Sep-18 | 0.96 | 0.92 | 0.89 | 1.40 | 1.78 |
Year Ending Dec-18 | 3.70 | 3.73 | 3.78 | 4.64 | 4.30 |
Year Ending Dec-19 | 4.18 | 4.20 | 4.19 | 4.36 | 6.48 |
Estimates Revisions Summary
Last Week | Last 4 Weeks | |||
---|---|---|---|---|
Number Of Revisions: | Up | Down | Up | Down |
Revenue | ||||
Quarter Ending Jun-18 | 0 | 1 | 0 | 1 |
Quarter Ending Sep-18 | 0 | 1 | 0 | 1 |
Year Ending Dec-18 | 0 | 1 | 0 | 2 |
Year Ending Dec-19 | 0 | 1 | 0 | 2 |
Earnings | ||||
Quarter Ending Jun-18 | 1 | 0 | 1 | 0 |
Quarter Ending Sep-18 | 1 | 0 | 1 | 0 |
Year Ending Dec-18 | 0 | 1 | 0 | 2 |
Year Ending Dec-19 | 0 | 1 | 1 | 1 |
- BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA
- BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent
- BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58
- BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing
- BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals